Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MGAM | O43451 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | SI | P14410 | 4/20 | 0.58 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | QPCT | Q16769 | 2/20 | 0.46 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17713905 | 0.91 | KDM4E (0.76) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL6538920 | 0.87 | RAB9A (0.94) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL7323592 | 0.87 | RAB9A (1.00) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6132856 | 0.87 | RAB9A (0.62) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL16479583 | 0.84 | RAB9A (0.78) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL21156447 | 0.82 | RAB9A (0.74) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL12939777 | 0.82 | RAB9A (0.74) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL677615 | 0.81 | RAB9A (0.50) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL6539262 | 0.79 | KDM4E (0.97) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL7316607 | 0.79 | NR1H4 (0.65) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204379-A1 | POLYPEPTIDE COMPOUND | Astellas Pharma Inc. (JP) | 2010-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | VIP, ANPEP, NPEPPS | RAB9A 3040/4885MAPT 3126/4885LMNA 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.